Prothymosin-α and parathymosin expression predicts poor prognosis in squamous and adenosquamous carcinomas of the gallbladder

  • Authors:
    • Kang Chen
    • Li Xiong
    • Zhuling Yang
    • Shengfu Huang
    • Rong Zeng
    • Xiongying Miao
  • View Affiliations

  • Published online on: January 19, 2018     https://doi.org/10.3892/ol.2018.7824
  • Pages: 4485-4494
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The present study aimed to investigate the expression patterns of prothymosin-α (PTMA) and parathymosin (PTMS) in patients with squamous cell carcinoma (SCC), adenosquamous cell carcinoma (ASC) and adenocarcinoma (AC) of the gallbladder, and to assess their association with the clinicopathological characteristics and prognosis of the patients. A retrospective analysis of data pertaining to patients with SCC/ASC (n=46) and AC (n=80) of the gallbladder, who were treated with surgical resection, was conducted. Kaplan‑Meier survival analysis was also performed to assess the correlation of the expression pattern with survival. The results revealed a higher percentage of patients with a large tumor diameter (>3 cm) in the SCC/ASC group as compared with those in the AC group (P<0.05). No significant differences were observed between patients with SCC/ASC and those with AC with respect to the patient sex, presence of gallstones, TNM stage, lymph node metastasis, invasive growth into anatomically contiguous structures, surgical methods used, survival rate, and the expression levels of PTMA and PTMA (P>0.05). However, positive expression of PTMA and PTMA was associated with tumor size, TNM stage, lymph node metastasis, locally invasive growth, and treatment with radical resection in patients with SCC/ASC and AC (P<0.05). In addition, positive expression of PTMA and PTMA was observed in a significantly lower number of patients with advanced AC as compared with those in early AC (P<0.05), while these expression levels were also associated with shorter survival in the SCC/ASC group and AC group (P<0.05). Cox multivariate analysis also demonstrated a negative correlation between PTMA and PTMA levels, and the postoperative survival rate in the two groups. In conclusion, the present study indicated that the expression levels of PTMA and PTMA were closely associated with the tumorigenesis and progression of SCC, ASC and AC of the gallbladder. Positive expression of PTMA and PTMA may serve as a valuable prognostic factor in these patients.

References

1 

Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, Saka B, Losada H, Bagci P and Adsay NV: Squamous cell and adenosquamous carcinomas of the gallbladder: Clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 24:1069–1078. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Kim WS, Jang KT, Choi DW, Choi SH, Heo JS, You DD and Lee HG: Clinicopathologic analysis of adenosquamous/squamous cell carcinoma of the gallbladder. J Surg Oncol. 103:239–242. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Kondo M, Dono K, Sakon M, Shimizu J, Nagano H, Nakamori S, Umeshita K, Wakasa K and Monden M: Adenosquamous carcinoma of the gallbladder. Hepatogastroenterology. 49:1230–1234. 2002.PubMed/NCBI

4 

Nishihara K, Nagai E, Izumi Y, Yamaguchi K and Tsuneyoshi M: Adenosquamous carcinoma of the gallbladder: A clinicopathological, immunohistochemical and flow-cytometric study of twenty cases. Jpn J Cancer Res. 85:389–399. 1994. View Article : Google Scholar : PubMed/NCBI

5 

Mingoli A, Brachini G, Petroni R, Antoniozzi A, Cavaliere F, Simonelli L, Chirletti P and Modini C: Squamous and adenosquamous cell carcinomas of the gallbladder. J Exp Clin Cancer Res. 24:143–150. 2005.PubMed/NCBI

6 

Chan KM, Yu MC, Lee WC, Jan YY and Chen MF: Adenosquamous/squamous cell carcinoma of the gallbladder. J Surg Oncol. 95:129–134. 2007. View Article : Google Scholar : PubMed/NCBI

7 

Rekik W, Ben Fadhel C, Boufaroua AL, Mestiri H, Khalfallah MT, Bouraoui S and Mzabi-Rgaya S: Case report: Primary pure squamous cell carcinoma of the gallbladder. J Visc Surg. 148:e149–e151. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Oohashi Y, Shirai Y, Wakai T, Nagakura S, Watanabe H and Hatakeyama K: Adenosquamous carcinoma of the gallbladder warrants resection only if curative resection is feasible. Cancer. 94:3000–3005. 2002. View Article : Google Scholar : PubMed/NCBI

9 

Haritos AA, Goodall GJ and Horecker BL: Prothymosin alpha: Isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proc Natl Acad Sci USA. 81:pp. 1008–1011. 1984; View Article : Google Scholar : PubMed/NCBI

10 

Letsas KP and Frangou-Lazaridis M: Surfing on prothymosin alpha proliferation and anti-apoptotic properties. Neoplasma. 53:92–96. 2006.PubMed/NCBI

11 

Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J, Donnelly J, Burns D, Ng SC, Rosenberg S and Wang X: Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science. 299:223–226. 2003. View Article : Google Scholar : PubMed/NCBI

12 

Jou YC, Tung CL, Tsai YS, Shen CH, Syue-Yi C, Shiau AL, Tsai HT, Wu CL and Tzai TS: Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma. Urology. 74:951–957. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Letsas KP, Vartholomatos G, Tsepi C, Tsatsoulis A and Frangou-Lazaridis M: Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: Novel proliferation markers? Neoplasma. 54:57–62. 2007.PubMed/NCBI

14 

Wang M, Pan JY, Song GR, Chen HB, An LJ and Qu SX: Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: Correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol. 33:195–201. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Zhang M, Cui F, Lu S, Lu H, Jiang T, Chen J, Zhang X, Jin Y, Peng Z and Tang H: Increased expression of prothymosin-α, independently or combined with TP53, correlates with poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 7:4867–4876. 2014.PubMed/NCBI

16 

Frangou-Lazaridis M, Clinton M, Goodall GJ and Horecker BL: Prothymosin alpha and parathymosin: Amino acid sequences deduced from the cloned rat spleen cDNAs. Arch Biochem Biophys. 263:305–310. 1988. View Article : Google Scholar : PubMed/NCBI

17 

Clinton M, Frangou-Lazaridis M, Panneerselvam C and Horecker BL: The sequence of human parathymosin deduced from a cloned human kidney cDNA. Biochem Biophys Res Commun. 158:855–862. 1989. View Article : Google Scholar : PubMed/NCBI

18 

Haritos AA, Salvin SB, Blacher R, Stein S and Horecker BL: Parathymosin alpha: A peptide from rat tissues with structural homology to prothymosin alpha. Proc Natl Acad Sci USA. 82:pp. 1050–1053. 1985; View Article : Google Scholar : PubMed/NCBI

19 

Hannappel E and Huff T: The thymosins. Prothymosin alpha, parathymosin, and beta-thymosins: Structure and function. Vitam Horm. 66:257–296. 2003. View Article : Google Scholar : PubMed/NCBI

20 

Vareli K, Frangou-Lazaridis M, van der Kraan I, Tsolas O and van Driel R: Nuclear distribution of prothymosin alpha and parathymosin: Evidence that prothymosin alpha is associated with RNA synthesis processing and parathymosin with early DNA replication. Exp Cell Res. 257:152–161. 2000. View Article : Google Scholar : PubMed/NCBI

21 

Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G and Nervi F: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar : PubMed/NCBI

22 

Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging Manual and the Future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI

23 

Hamilton SR and Aaltonen LA: Patholigy and Genetics of Tumours of the Digestive System. IARC Press; Lyon: 2000

24 

Okamoto K and Isohashi F: Purification and primary structure of a macromolecular-translocation inhibitor II of glucocorticoid-receptor binding to nuclei from rat liver. Inhibitor II is the 11.5-kDa Zn2+-binding protein (parathymosin). Eur J Biochem. 267:155–162. 2000. View Article : Google Scholar : PubMed/NCBI

25 

Hoch K and Volk DE: Structures of thymosin proteins. Vitam Horm. 102:1–24. 2016. View Article : Google Scholar : PubMed/NCBI

26 

Mosoian A, Teixeira A, High AA, Christian RE, Hunt DF, Shabanowitz J, Liu X and Klotman M: Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages. J Virol. 80:9200–9206. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, K., Xiong, L., Yang, Z., Huang, S., Zeng, R., & Miao, X. (2018). Prothymosin-α and parathymosin expression predicts poor prognosis in squamous and adenosquamous carcinomas of the gallbladder. Oncology Letters, 15, 4485-4494. https://doi.org/10.3892/ol.2018.7824
MLA
Chen, K., Xiong, L., Yang, Z., Huang, S., Zeng, R., Miao, X."Prothymosin-α and parathymosin expression predicts poor prognosis in squamous and adenosquamous carcinomas of the gallbladder". Oncology Letters 15.4 (2018): 4485-4494.
Chicago
Chen, K., Xiong, L., Yang, Z., Huang, S., Zeng, R., Miao, X."Prothymosin-α and parathymosin expression predicts poor prognosis in squamous and adenosquamous carcinomas of the gallbladder". Oncology Letters 15, no. 4 (2018): 4485-4494. https://doi.org/10.3892/ol.2018.7824